avapro has been researched along with Body Weight in 21 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Irbesartan and captopril significantly reduced systolic pressure and produced similar rightward shifts in the angiotensin I dose-response curve." | 5.30 | Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. ( Carraway, JW; Holycross, BJ; McCune, SA; Park, S; Radin, MJ, 1999) |
| "Myocardial fibrosis is one of the serious pathological changes, so investigating the pathogenesis of myocardial fibrosis has the significant value." | 1.51 | Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model. ( Guanjun, Z; Heng, Z; Hongwei, Y; Jie, H; Jie, T; Junfeng, H; Qin, G; Ruiping, C; Xingyu, L; Yingyan, F; Zhenghong, L, 2019) |
| "Treatment with dapagliflozin, irbesartan, and especially their combination, produced significant reduction in albuminuria, improved renal function parameters, increased sRAGE level and improved inflammatory and oxidative markers, together with amelioration of renal histopathological changes." | 1.48 | Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. ( Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N, 2018) |
| " Thus, optimal neprilysin inhibitor dosing reveals additional cardioprotective effects on top of AT1 receptor blockade in renin-dependent hypertension." | 1.42 | Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. ( Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; de Vries, R; Domenig, O; Friesema, EC; Garrelds, IM; Hoorn, EJ; Jan Danser, AH; Leijten, FP; Poglitsch, M; Roksnoer, LC; van Veghel, R, 2015) |
| "Proteinuria was markedly attenuated in the sulodexide-treated groups." | 1.38 | Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. ( Chen, XM; Li, P; Ma, LL; Wang, JZ; Wei, RB; Xie, RJ; Xie, YS; Yin, M, 2012) |
| " After chronic administration of irbesartan (21 days at 50 mg." | 1.31 | Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. ( Henriksen, EJ; Jacob, S; Kinnick, TR; Krekler, M; Teachey, MK, 2001) |
| "Post-MI hypertrophy was associated with substantial increases in the messenger RNA (mRNA) expression of atrial natriuretic peptide (ANP), but no significant changes in SERCA or PLB levels." | 1.30 | Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. ( Ambrose, J; Giraud, GD; Greenberg, BH; Muldoon, L; Perkins, KD; Pribnow, DG, 1999) |
| " Irbesartan and captopril significantly reduced systolic pressure and produced similar rightward shifts in the angiotensin I dose-response curve." | 1.30 | Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. ( Carraway, JW; Holycross, BJ; McCune, SA; Park, S; Radin, MJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Wahab, AF | 1 |
| Bamagous, GA | 1 |
| Al-Harizy, RM | 1 |
| ElSawy, NA | 1 |
| Shahzad, N | 1 |
| Ibrahim, IA | 1 |
| Ghamdi, SSA | 1 |
| Hongwei, Y | 1 |
| Ruiping, C | 1 |
| Yingyan, F | 1 |
| Guanjun, Z | 1 |
| Jie, H | 1 |
| Xingyu, L | 1 |
| Jie, T | 1 |
| Zhenghong, L | 1 |
| Qin, G | 1 |
| Junfeng, H | 1 |
| Heng, Z | 1 |
| Maeda, A | 1 |
| Tamura, K | 1 |
| Wakui, H | 1 |
| Ohsawa, M | 1 |
| Azushima, K | 1 |
| Uneda, K | 1 |
| Kobayashi, R | 1 |
| Tsurumi-Ikeya, Y | 1 |
| Kanaoka, T | 1 |
| Dejima, T | 1 |
| Ohki, K | 1 |
| Haku, S | 1 |
| Yamashita, A | 1 |
| Umemura, S | 1 |
| Zhao, Y | 1 |
| Fukao, K | 1 |
| Zhao, S | 1 |
| Watanabe, A | 1 |
| Hamada, T | 1 |
| Yamasaki, K | 1 |
| Shimizu, Y | 1 |
| Kubo, N | 1 |
| Ukon, N | 1 |
| Nakano, T | 1 |
| Tamaki, N | 1 |
| Kuge, Y | 1 |
| Roksnoer, LC | 1 |
| van Veghel, R | 1 |
| de Vries, R | 1 |
| Garrelds, IM | 1 |
| Bhaggoe, UM | 1 |
| Friesema, EC | 1 |
| Leijten, FP | 1 |
| Poglitsch, M | 1 |
| Domenig, O | 1 |
| Clahsen-van Groningen, MC | 1 |
| Hoorn, EJ | 1 |
| Jan Danser, AH | 1 |
| Batenburg, WW | 1 |
| Lewin, AJ | 1 |
| Weir, MR | 1 |
| Kobayashi, T | 1 |
| Akiyama, Y | 1 |
| Akiyama, N | 1 |
| Katoh, H | 1 |
| Yamamoto, S | 1 |
| Funatsuki, K | 1 |
| Yanagimoto, T | 1 |
| Notoya, M | 1 |
| Asakura, K | 1 |
| Shinosaki, T | 1 |
| Hanasaki, K | 1 |
| De Luis, DA | 1 |
| Conde, R | 1 |
| Gonzalez Sagrado, M | 1 |
| Aller, R | 1 |
| Izaola, O | 1 |
| Perez Castrillon, JL | 1 |
| Romero, E | 1 |
| Castro, MJ | 1 |
| Li, P | 1 |
| Ma, LL | 1 |
| Xie, RJ | 1 |
| Xie, YS | 1 |
| Wei, RB | 1 |
| Yin, M | 1 |
| Wang, JZ | 1 |
| Chen, XM | 1 |
| Riveiro, A | 1 |
| Mosquera, A | 1 |
| Alonso, M | 1 |
| Calvo, C | 1 |
| Pham-Dang, ML | 1 |
| Clement, R | 1 |
| Mercier, I | 1 |
| Calderone, A | 1 |
| Shimamura, T | 1 |
| Masui, M | 1 |
| Torii, M | 1 |
| Nakajima, M | 1 |
| Tikellis, C | 1 |
| Wookey, PJ | 1 |
| Candido, R | 1 |
| Andrikopoulos, S | 1 |
| Thomas, MC | 1 |
| Cooper, ME | 1 |
| Janiak, P | 1 |
| Bidouard, JP | 1 |
| Cadrouvele, C | 1 |
| Poirier, B | 1 |
| Gouraud, L | 1 |
| Grataloup, Y | 1 |
| Pierre, F | 1 |
| Bruneval, P | 1 |
| O'Connor, SE | 1 |
| Herbert, JM | 1 |
| Merkus, D | 1 |
| Haitsma, DB | 1 |
| Sorop, O | 1 |
| Boomsma, F | 2 |
| de Beer, VJ | 1 |
| Lamers, JM | 1 |
| Verdouw, PD | 1 |
| Duncker, DJ | 1 |
| van den Meiracker, AH | 1 |
| Admiraal, PJ | 1 |
| Janssen, JA | 1 |
| Kroodsma, JM | 1 |
| de Ronde, WA | 1 |
| Sissmann, J | 1 |
| Blankestijn, PJ | 1 |
| Mulder, PG | 1 |
| Man In 't Veld, AJ | 1 |
| Ambrose, J | 1 |
| Pribnow, DG | 1 |
| Giraud, GD | 1 |
| Perkins, KD | 1 |
| Muldoon, L | 1 |
| Greenberg, BH | 1 |
| Carraway, JW | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Holycross, BJ | 1 |
| Radin, MJ | 1 |
| Intengan, HD | 1 |
| Thibault, G | 1 |
| Li, JS | 1 |
| Schiffrin, EL | 1 |
| Henriksen, EJ | 1 |
| Jacob, S | 1 |
| Kinnick, TR | 1 |
| Teachey, MK | 1 |
| Krekler, M | 1 |
| Ortlepp, JR | 1 |
| Breuer, J | 1 |
| Eitner, F | 1 |
| Kluge, K | 1 |
| Kluge, R | 1 |
| Floege, J | 1 |
| Hollweg, G | 1 |
| Hanrath, P | 1 |
| Joost, HG | 1 |
3 trials available for avapro and Body Weight
| Article | Year |
|---|---|
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diver
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Body Mass Index; Body Weight; Cluster Analysis; D | 2008 |
Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Biphenyl Compoun | 2010 |
Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Weigh | 1995 |
18 other studies available for avapro and Body Weight
| Article | Year |
|---|---|
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic | 2018 |
Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.
Topics: Animals; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; | 2019 |
Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disorders.
Topics: Adaptor Proteins, Signal Transducing; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Anima | 2014 |
Irbesartan attenuates atherosclerosis in Watanabe heritable hyperlipidemic rabbits: noninvasive imaging of inflammation by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Autoradiography; Biphenyl Compounds; Body Weight; | 2015 |
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Atrial Natriuretic Factor; Biph | 2015 |
Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biological Transport; Biphenyl Compounds; Body Wei | 2010 |
Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Bl | 2012 |
Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless of oestrogen status.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; | 2002 |
Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Body Weight; F | 2003 |
Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 2004 |
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Biphenyl Compounds; Blood Glucose; Blo | 2004 |
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2006 |
Coronary vasoconstrictor influence of angiotensin II is reduced in remodeled myocardium after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Body Weight; C | 2006 |
Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphe | 1999 |
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1999 |
Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats : effects of angiotensin receptor antagonism and converting enzyme inhibition.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1999 |
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
Topics: Angiotensin Receptor Antagonists; Animals; Area Under Curve; Biological Transport; Biphenyl Compound | 2001 |
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |